Brief: Intelgenx Receives Complete Response Letter From FDA For Xiromed-Partnered Buprenorphine Buccal Film
27/04/2023 14:27
April 27 (Reuters) - Intelgenx Technologies Corp
IGX.TO :
* INTELGENX ANNOUNCES RECEIPT OF COMPLETE RESPONSE LETTER
FROM THE
FDA FOR XIROMED-PARTNERED BUPRENORPHINE BUCCAL FILM
* INTELGENX ANNOUNCES RECEIPT OF COMPLETE RESPONSE LETTER
FROM THE
FDA FOR XIROMED-PARTNERED BUPRENORPHINE BUCCAL FILM
* INTELGENX TECHNOLOGIES CORP - XIROMED AND INTELGENX WILL
CONTACT
FDA TO DISCUSS CRL AND ASSESS FILING OF A REQUEST FOR
RECONSIDERATION OF CRL
Source text for Eikon: ID:nGNX9KC6Ql
Further company coverage: IGX.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intelgenx Technologies
See all newsBrief: Intelgenx Obtains Court-Approval Of Sale & Investment Solicitation Process
Brief: Intelgenx Initiates Restructuring Proceedings Under CCAA To Implement Review Of Its Strategic Alternatives
Brief: Intelgenx Initiates Restructuring Proceedings Under The CCAA
Brief: IntelGenx Says First Parkinson’s Disease Patients Dosed With Montelukast VersaFilm in Mid-Stage Clinical Trial
Brief: IntelGenx Updates Status Of Buprenorphine Buccal Film ANDA